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Unfortunately an incorrect Table 1 was published. Please find below the correct table. Table 1Time to progression in different patient subgroups \[57\]SubgroupLetrozoleTamoxifenDominant disease site: soft tissue*n*113115Median TTP12.1 months6.4 monthsDominant disease site: bone*n*145131Median TTP9.5 months6.3 monthsDominant disease site: viscera*n*195208Median TTP8.3 months4.6 monthsPatients who had received prior Antiestrogen*n*8483Median TTP8.9 months5.9 monthsHazard ratio (95% CI)^a^0.60 (0.43, 0.84)HR-positive*n*294305Median TTP9.4 months6.0 monthsHazard ratio (95% CI)^a^0.69 (0.58, 0.83)HR-unknown*n*159149Median TTP9.2 months6.0 monthsHazard ratio (95% CI)^a^0.77 (0.60, 0.99)TTP, time to progression; CI, confidence interval; HR, hormone receptor^a^Hazard ratios \<1.0 indicate superiority for letrozole relative to tamoxifen

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10549-007-9527-6>
